The 4 most recent market catalysts affecting $ALLO, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Oct 29, 2026
Corporate Catalyst
Neutral
Impact 65
Allogene Therapeutics Announces November Investor Events Highlighting Q3 Results and Initial ALLO-329 Autoimmune Clinical Data
Allogene Therapeutics is announcing two key investor events in November 2026: its Q3 2026 earnings call and a webinar to present preliminary Phase 1 data for ALLO-329 in autoimmune…
Sep 2, 2026
Corporate Catalyst
Neutral
Impact 65
Allogene Therapeutics EVP And CFO Geoffrey Parker To Retire, Effective November 6
Allogene Therapeutics (ALLO) announced that its EVP and CFO, Geoffrey Parker, will retire on November 6, 2026. This is a significant executive change, as the CFO plays a crucial ro…
Aug 12, 2026
Corporate Catalyst
Neutral
Impact 55
Allogene Therapeutics Files Prospectus For $500M Offering
Allogene Therapeutics filed an S-3 shelf registration statement, allowing them to offer and sell up to $500 million in various securities (common stock, preferred stock, debt secur…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.